Modern approaches to the treatment of patients with type 2 diabetes mellitus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Type 2 diabetes mellitus - a chronic disease characterized by a gradual progressive decline in β-cell function. The antihyperglycemic therapy should not only ensure the achievement of the target values of glycemic control with minimal risk of side effects, including hypoglycemia, but hold down achieved glycemic control for a long time. Currently, there are different classes of antihyperglycemic drugs (AHDs). The article analyzes the effectiveness of main AHDs (sulfonylureas, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and insulin) in combination with metformin.

Full Text

Restricted Access

About the authors

M. B Antsiferov

SBHCI “Endocrinological Dispensary" of the Moscow Healthcare Department

V. V Fadeev

FSBEI HE First MSMU n.a. I.M. Sechenov of RMH

Department of Endocrinology

T. B Morgunova

FSBEI HE First MSMU n.a. I.M. Sechenov of RMH

Email: tanmorgun@mail.ru
Department of Endocrinology PhD

References

  1. Дедов И.И., Шестакова М.В., Галстян Г.Р., Григорян О.Р., Есаян Р.М., Калашников В.Ю., Кураева Т.Л., Липатов Д.В., Майоров А.Ю., Петеркова В.А., Смирнова О.М., Старостина Е.Г., Суркова Е.В., Сухарева О.Ю., Токмакова А.Ю., Шамхалова М.Ш., Ярек-Мартынова И.Р. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск). Сахарный диабет. 2015;18(1S):1-112.
  2. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-49.
  3. Garber A.J., Abrahamson M.J., Barzilay J.I., et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract. 2016;22(1):84-113.
  4. American Diabetes Association. Approaches to glycemic treatment. Diabetes Care. 2015;38(Suppl):41-8.
  5. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res. Clin. Pract. 2014;104(1):1-52.
  6. Sharma M., Nazareth I., Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210.
  7. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., Kravitz B.G., Lachin J.M., O'Neill M.C., Zinman B., Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006;355(23):2427-43.
  8. Gurgle H.E, White K., McAdam-Marx C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag. 2016;12:239-49.
  9. McIntosh B., Cameron C., Singh S.R., Yu C., Ahuja T., Welton N.J., Dahl M. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35-48.
  10. Mishriky B.M., Cummings D.M., Tanenberg R.J. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2015;109(2):378-88.
  11. Seck T., Nauck M., Sheng D., et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int. J. Clin. Pract. 2010;64(5):562-76.
  12. Göke B., Gallwitz B., Eriksson J.G., Hellqvist À., Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int. J. Clin. Pract. 2013;67(4):307-16.
  13. Gallwitz B., Rosenstock J., Rauch T., Bhattacharya S., Patel S., von Eynatten M., Dugi K.A., Woerle H.J. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-83.
  14. Matthews D.R., Dejager S., Ahren B., Fonseca V., Ferrannini E., Couturier A., Foley J.E., Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes. Metab. 2010;12(9):780-89.
  15. Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B. ,Navre M., Shi L., Skene R.J., Asakawa T., Takeuchi K., Xu R., Webb D.R., Gwaltney S.L. 2nd. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 2007;50:2297-300.
  16. Christopher R., Covington P., Davenport M., Fleck P., Mekki Q.A., Wann E.R., Karim A. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidylpeptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther. 2008; 30:513-27.
  17. Del Prato S., Camisasca R., Wilson C., Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin. Diabetes Obes. Metab. 2014;16(12):1239-46.
  18. Del Prato S., Fleck P., Wilson C., Chaudhari P. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes Obes. Metab. 2016;18(6):623-27.
  19. Garber A., Henry R.R., Ratner R., Hale P., Chang C.T., Bode B. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes. Metab. 2011;13(4):348-56.
  20. Gallwitz B., Guzman J., Dotta F., Guerci B., Sim O.R., Basson B.R., Festa A., Kiljahski J., Sapin H., Trautmann M., Schernthaner G. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012;379(9833):2270-78.
  21. Leiter L.A., Yoon K.H., Arias P., Langslet G., Xie J., Balis D.A., Millington D., Vercruysse F., Canovatchel W., Meininger G. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355-64.
  22. Ridderstràle M., Andersen K.R., Zeller C., Kim G., Woerle H.J., Broedl U.C. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet. Diabetes Endocrinol. 2014;2(9):691-700.
  23. Nauck M.A., Del Prato S., Durân-Garcia S., Rohwedder K., Langkilde A.M., Sugg J., Parikh S.J. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes. Metab. 2014;16(11): 1111-20.
  24. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., Broedl U.C., Inzucchi S.E. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015;373(22):2117-28.
  25. Nathan D.M., Buse J.B., Kahn S.E., Krause-Steinrauf H., Larkin M.E., Staten M., Wexler D., Lachin J.M. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36(8):2254-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies